KEYTRUDA® (pembrolizumab) KEYNOTE-590 clinical data presentation

Prescribing Information and SmPC (Great Britain) & Prescribing Information and SmPC (Northern Ireland) [External links]

PDF, 3.05 MB

The KEYNOTE-590 study explores KEYTRUDA (pembrolizumab) in combination with chemotherapy for patients with locally advanced or metastatic oesophageal cancer whose tumours express a PD-L1 CPS ≥10 score. This slide deck includes information on the study design, trial endpoints, efficacy and safety.

CPS = Combined Positive Score; PD-L1 = Programmed Death Ligand 1.

More information about KEYTRUDA® (pembrolizumab) in locally advanced unresectable or metastatic oesophageal cancer:

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) 
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website